NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NanoCell Therapeutics

NanoCell Therapeutics

Private
Wayne, PennsylvaniaHealthcare & Life Scienceshttps://nanocelltx.com/

Last Round

Grant

Aug 14, 2025

Total Funding Raised

$4.39M

Company Overview

NanoCell Therapeutics is a biotechnology company that develops non-viral, DNA-based in vivo gene therapy platforms for the treatment of oncology and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

in vivo gene therapylipid nanoparticleLNPCAR-T therapyminicircle DNAgene deliverycell engineeringRNA-transposasenon-viral deliveryoff-the-shelf CAR-Tnext-gen biotechbiotech R&Dprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NanoCell Therapeutics Comparables

Compare NanoCell Therapeutics with similar companies based on industry and business-model similarity.

NanoCell Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ensoma
82%
Aera Therapeutics
82%
Gilead Sciences
82%

NanoCell Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 14, 2025
SeedJun 16, 2025
GrantJan 4, 2023

Key People

Founding team and executive leadership

Jacek Lubelski

Chief Technology Officer

Executive Team

NanoCell Therapeutics Investors

Notable investors and investment history

NanoCell Therapeutics investors
InvestorRounds
Eureka NetworkGrant
Institute for Follicular Lymphoma InnovationSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 2, 2025

    Monthly visitors grew 1845% MoM, from 49 to 953.

NanoCell Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NanoCell Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NanoCell Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWayne, Pennsylvania
Employee Range17
Year Founded2021
Last FundingAug 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.